WO2022126124A1 - Radiopaque marking compositions and delivery thereof - Google Patents
Radiopaque marking compositions and delivery thereof Download PDFInfo
- Publication number
- WO2022126124A1 WO2022126124A1 PCT/US2021/072842 US2021072842W WO2022126124A1 WO 2022126124 A1 WO2022126124 A1 WO 2022126124A1 US 2021072842 W US2021072842 W US 2021072842W WO 2022126124 A1 WO2022126124 A1 WO 2022126124A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radiopaque
- polymer
- topical
- silicone
- substance
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000002156 mixing Methods 0.000 claims abstract description 36
- 229920005573 silicon-containing polymer Polymers 0.000 claims abstract description 36
- 229920000642 polymer Polymers 0.000 claims description 89
- 230000000699 topical effect Effects 0.000 claims description 89
- 239000000126 substance Substances 0.000 claims description 65
- 230000009977 dual effect Effects 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 229920001296 polysiloxane Polymers 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004970 Chain extender Substances 0.000 claims description 7
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims description 7
- 239000004971 Cross linker Substances 0.000 claims description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229910021485 fumed silica Inorganic materials 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 description 18
- 230000007246 mechanism Effects 0.000 description 18
- 239000003550 marker Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 238000002591 computed tomography Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- -1 siloxanes Chemical class 0.000 description 7
- 229920002554 vinyl polymer Polymers 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940064804 betadine Drugs 0.000 description 3
- 239000001055 blue pigment Substances 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002266 amputation Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000012463 white pigment Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000013131 cardiovascular procedure Methods 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 238000002675 image-guided surgery Methods 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 238000012273 nephrostomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
Definitions
- This disclosure relates to radiopaque marking mediums that are also visible in normal light, and particularly to topical radiopaque marking substances and delivery mechanisms therefor.
- Topical radiopaque markings are used to delineate anatomical locations in a variety of clinical settings and scenarios.
- image-guided surgery topical markings are used to provide a precise correlation between the patient and their scanned images. Examples include the following:
- diagnostic imaging topical markings are used to define anatomical locations and to orient the interpreting clinician.
- cardiovascular surgery topical markings are used to define vascular access sites, to size anatomic organs, to define implant location, and to size implants.
- topical markings may be used to specifically guide amputation location.
- topical markings are used to guide procedures like CT-guided lung biopsy.
- Bone screws - marking skin entry site Biliary intervention - triangulating anatomy
- Ablation - uses picture of stick area, line up with laser, prep over (chlorohexidine), then puncture through x-marks
- Chest tube placement - targeting with CT and making mark with CT and go through with x-ray G-tube placement - mark colon on scan as a reference point to avoid
- Nephrostomy tube placement - mark relevant structures to avoid Fistula de-clotting; Stent placement; and, Bone/wire fixation in plastic surgery.
- U.S. Patent No. 9,861 ,449 entitled Radiopaque Marking Implant discloses a crayon-like marker that applies a topical marking. However, the marking is prone to smearing and is not easily and/or cleanly removed from a patient’s skin.
- U.S. Patent No. 10,709,800 entitled Radiopaque Writing Instruments and Methods of Use discloses a liquid marker used to apply a topical marking. However, the marking is prone to smearing, does not apply evenly, dries too slowly and is not easily removed from the patient’s skin.
- compositions and devices for marking a patient's skin or a covering thereon include compositions and devices for marking a patient's skin or a covering thereon.
- a marking composition according to this disclosure which may also be referred to as an “ink,” may provide a mark that is visible to an individual when viewed directly and in images obtained from one or more common imaging modalities (e.g., x-ray, fluoroscopy, CT, etc.).
- the marking composition may be formulated to enable a clinician to mark a patient's skin clearly and accurately to provide a well-defined and unambiguous marking that contrasts with the surface to which it is applied and that indicates the identity of the patient, the site (e.g., surgical location, etc.) where the patient is to be treated, and/or the procedure, or treatment approach, to be taken, including any patient-specific details of the procedure.
- the marking composition of the present disclosure may be formulated by two components, each of which being composed by at least 50% radiopaque agent in order to provide adequate visibility under radiologic imaging. Lower concentrations of radiopaque agent may be used for more viscous formulations that apply more thickly; however, this increase in viscosity leads to undesirable delivery properties.
- the radiopaque agent may itself be composed of multiple radiopaque agents. [0014] In one embodiment the two components are each composed of around 53.6% radiopaque agent. In one embodiment the two components are each composed of around 54% radiopaque agent.
- the composition of the at least two components should be a minimum of 50% radiopaque agent.
- the applied layer thickness is preferred to be less than 1.5mm.
- the components need not each be composed of at least 50% radiopaque agent as long as the composite marking composition, comprised of the two components, of the present disclosure itself is composed of at least 50% radiopaque agent.
- the two components could each be composed of 25% radiopaque agent and 75% radiopaque agent, respectively, such that, when combined, the composite marking composition is at least 50% radiopaque agent.
- the two components may be comprised of a silicone base.
- the two components are further comprised of a silicone polymer that includes silica, either particulate silica or fumed silica.
- a topical radiopaque marking composition of the present disclosure may include a first radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the first radiopaque polymer component; and a second radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the second radiopaque polymer component; wherein the first radiopaque polymer component and said second radiopaque polymer component are mixable to form one topical radiopaque marking substance.
- a method of applying a topical radiopaque marking substance of the present disclosure may include providing a radiopaque polymer A and a radiopaque polymer B, each of which having a radiopaque agent content of at least 50% and then mixing the radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance; and performing the mixing just prior to applying the topical radiopaque marking substance to a target site.
- a method of making a topical radiopaque marking substance of the present disclosure may include providing a silicone base; formulating a silicone polymer A and a silicone polymer B from the silicone base wherein the composition of silicone polymer A is different than the composition of silicone polymer A; adding at least one radiopaque substance to each of silicone polymer A and silicone polymer B to form a radiopaque polymer A and a radiopaque polymer B, respectively; and, mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
- a method of making a topical radiopaque marking substance of the present disclosure may include providing a silicone base; formulating a silicone polymer from said silicone base; adding at least one radiopaque substance to the silicone polymer to form a radiopaque base; formulating a radiopaque polymer A and a radiopaque polymer B from the radiopaque base, wherein the composition of radiopaque polymer A is different from the composition of radiopaque polymer B; and mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
- a device for delivering a topical radiopaque marking substance in accordance with the present disclosure may include dual chambers disposed in the housing, one chamber containing a silicone based radiopaque polymer A and one chamber containing a silicone based radiopaque polymer B; a mixer disposed at a distal end of the housing; a dual chamber plunger interoperative with the dual chamber; a spring for urging movement of the dual chamber plunger into said dual chamber; and a push button to actuate movement of the dual chamber plunger.
- FIG. 1 is two photographs, both of the same hand with a topical radiopaque composition in accordance with the present disclosure, one photograph in normal light and one photograph under radiologic imaging;
- Fig. 2 is a photograph of an animal with a topical radiopaque composition in accordance with the present disclosure when viewed in normal light;
- Fig. 3 is a photograph of the animal of Fig. 2 when viewed under fluoroscopic radiologic imaging
- Fig. 4 is series of photographs of a topical radiopaque composition in accordance with the present disclosure, one under normal light and two under computed tomography (CT) imaging;
- CT computed tomography
- Fig. 5 is a photograph of a topical radiopaque composition in accordance with the present disclosure being removed from the skin of subject;
- Fig. 6 is a flow chart for a formulation of a topical radiopaque composition in accordance with the present disclosure
- Fig. 7 is a flow chart for a formulation of a topical radiopaque composition in accordance with the present disclosure
- Fig. 8 is a cross-sectional schematic view of a mixer and applicator mechanism for a dual component substance in accordance with the present disclosure
- Fig. 9 is a cross-sectional schematic view of a mixer and applicator mechanism for a dual component substance in accordance with the present disclosure
- FIG. 10 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure
- FIGs 11A-11 C are perspective views of a housing usable with a dual component mixer and applicator in accordance with the present disclosure
- FIG. 12 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure
- FIGs 13A-13B are perspective views of a housing usable with a dual component mixer and applicator in accordance with the present disclosure.
- Fig. 14 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure.
- This disclosure is directed to a topical freeform radiopaque marking composition and a marking mechanism useful in making clear and unambiguous markings on a patient in preparation for medical procedures such as surgeries and other procedures, and particularly in surgeries and procedures that require radiographic imaging (e.g., X-Ray, CT scanning, fluoroscopy, SPECT, MRI, PET-CT, MRA, nuclear medicine scans).
- the markings may identify the patient, one or more treatment sites on the patient, the procedure(s) to be conducted at each treatment site (e.g., surgical approaches, etc.), one or more anatomic landmarks, the interventional approach or the like.
- the markings are versatile and helpful both in surgeries and procedures that don’t require the aid of radiographic imaging and those that do.
- a topical freeform radiopaque marking composition in accordance with this disclosure is shown Figs. 1 -3 in connection with a procedure involving hand surgery (Fig. 1 ) and a procedure involving a vascular operation (Figs. 2-3) where the marking composition is clearly seen both under normal vision and in radiographic imaging.
- the topical freeform radiopaque marking composition in accordance with this disclosure is useful in CT imaging as shown in Fig. 4.
- a grid is drawn on a torso phantom in a simulated CT-guided lung biopsy. The far left photos is the composition in normal light and the remaining two photos show the composition in CT images. The marking composition is visible and shows no imaging artifact.
- the topical freeform radiopaque composition is also easily removable from the skin of a patient as shown in Fig. 5.
- a topical freeform radiopaque marking composition according to this disclosure has superior properties in its viewing properties under radiographic imaging, in its non-smearing properties, in its ease in removal from a patient’s skin; in its ease in delivery and in its versatility.
- the topical freeform radiopaque marking composition has a radiopaque agent that makes up at least 50% of the composition. Another reason may be that it is formulated from a silicone base. Another reason may be that its viscosity is in a range of 5000-7500 CPS, preferably 6500 CPS. Another reason may be that its cure time is in a range of 10 seconds to 3 minutes, and preferably 10 seconds to 60 seconds. Another reason may be that it is comprised of two components that polymerize and cross-link when mixed.
- the topical radiopaque marking composition of the present disclosure need not be formulated from only two components. As will be appreciated by one of skill in the art, more than two components could be used without departing from the scope of this disclosure and still arrive at a topical radiopaque marking composition that has at least 50% radiopaque composition, has a viscosity in a range of 5000-7500 CPS and a cure time in a range of 10 seconds to 3 minutes.
- the example formulations contained herein are not limiting to the scope of the invention..
- a topical freeform radiopaque marking composition may comprise two components which, when mixed together, provide a topical freeform radiopaque marking substance.
- Each component may include one or more radio-opaque components.
- Each component may include a silicone base.
- Each component may also include a pigment.
- Each component may include one or more of the following: a siloxane, a chain extender and a cross-linker.
- Each component may have a radiopaque agent of over 50%.
- a topical radiopaque marking composition of the present disclosure is non-limiting examples for a topical radiopaque marking composition of the present disclosure.
- a radiopaque marking composition that has at least 50% radiopaque agent, a viscosity in a range of 5000-7500 CPS and a cure time in a range of 10 seconds to 3 minutes.
- radiopaque agents and combinations thereof can differ from those disclosed in the examples and still result in a radiopaque marking composition in accordance with the present disclosure.
- Topical freeform radiopaque marking substance of the present disclosure may have the formulation set forth below:
- Example 1 Compared to prior art topical radiopaque marker substances (e.g., those mentioned in the patents identified above), the formulation of Example 1 was found to have improved curing times, negligible smearing, reduced preparation time of the application site (e.g., can use standard preparation like betadine and wipes), and is easily removed from the skin as shown in Fig. 5.
- the process by which the Radiopaque Polymer A and Radiopaque Polymer B of the chart above may be formed is where a Silicone Base is used to form a Silicone Polymer A and a Silicone Polymer B which, in turn, are used to make Radiopaque Polymer A and Radiopaque Polymer B, respectively.
- Radiopaque Polymer A and Radiopaque Polymer B are mixed together during ejection from an applicator onto, for example, a patient, in the form of a freeform topical radiopaque marking substance in accordance with this disclosure.
- the freeform topical radiopaque marker substance of Example 1 may be produced in the following manner:
- the silicone base is produced by mixing HMDZ treated precipitated silica with 10,000 vinyl siloxane.
- the silicone base and the vinyl siloxanes (VIN 70 & VIN 200) to be used in producing Silicone Polymer A and Silicone Polymer B (the “Silicone Polymers”) are weighed out in a container.
- radiopaque agents barium sulfate, sodium diatrizoate, and bismuth III oxide
- the radiopaque agents barium sulfate, sodium diatrizoate, and bismuth III oxide
- the viscosity of the mixture should be where it is pourable but once poured the mixture will not drip or run. In one embodiment the viscosity is in a range of 6,500 to 7,200 cps).
- the mixture is placed under a rotator-stator homogenizer and thoroughly mixed until the radiopaque agents are thoroughly dispersed. Once the mixture is homogenous, the mixture is split into two equal parts, Part A and Part B.
- White silicone pigment and a 3% platinum catalyst is added to Part A and mixed using a high-speed disperser blade
- Blue pigment, a chain extender (DH6) and a hydride cross linking agent is added to Part B and mixed using a high-speed disperser blade.
- the mixing process can take between 6-8 hours to achieve a desired viscosity.
- Part A and Part B mixtures are placed in a vacuum chamber until there are no visible bubbles.
- radiopaque polymer A and radiopaque polymer B of Example 1 are mixed when exiting an applicator.
- the two radiopaque polymers contain different agents that, when mixed, enable polymerization and cross-linking of the vinyl monomers via the formation of a siloxane bond.
- the resulting freeform topical radiopaque marker substance has a cure time of around 3 minutes and a viscosity of 5000 CPS.
- the shelf life of radiopaque polymer A and radiopaque polymer B of Example 1 is formulated to be 1 year.
- the freeform topical radiopaque marking substance may have a formulation as set forth below.
- Radiopaque Polymer A and Radiopaque Polymer B of the chart above may be formed is where a Silicone Base is used to form a Silicone Polymer which is then used to form a Radiopaque Base.
- the Radiopaque Base is then used to form a Radiopaque Polymer A and Radiopaque Polymer B, respectively.
- Radiopaque Polymer A and Radiopaque Polymer B are mixed together during ejection from an applicator onto, for example, a patient, in the form of a freeform topical radiopaque marking substance in accordance with this disclosure.
- the freeform topical radiopaque marker substance of Example 2 may be produced in the following manner:
- HMDZ treated fumed silica and 10,000 vinyl siloxane are mixed together to form a silicone base.
- a quality check may be performed to check viscosity and thixotropic index with expected values being those set forth in Fig. 7
- the silicone base is then mixed together with 200 vinyl siloxane in a plastic container using a Ross mixer to produce a silicone polymer. In one embodiment, the mixing is performed for 30 min.
- the viscosity of the silicone polymer after mixing at 2 RPM was 912 cps.
- the viscosity of the silicone polymer after mixing at 20 RPM was 896 cps.
- the Thixotropic Index of the silicone polymer was 1.018.
- a desired amount of silicone polymer is then move to stainless-steel container and fumed silica is added. Further mixing at high-speed using the ROSS mixer is performed.
- sodium diatrizoate is added.
- the sodium diatrizoate is added over a period of 10-15 minutes.
- the resulting radiopaque base is then placed under a rotor/stator mixer and mixed for 15 min.
- the viscosity may be checked for the expected values as set forth in Fig. 7.
- the viscosity of the radiopaque base is 6480 cps.
- the radiopaque base is then placed under vacuum until air is removed.
- Radiopaque base is then divided into 2 equal parts, a Part A and Part B.
- White pigment and 3% platinum catalyst are added to Part A while mixing under a ROSS mixer to form radiopaque polymer A.
- Part B is placed under a ROSS mixer and while mixing at a medium speed, blue silicone pigment is added. Once the blue pigment is thoroughly mixed in (e.g., 10-15 minutes) DH-6 (hydride chain extender) is added.
- DH-6 hydride chain extender
- the resulting compound constitutes radiopaque polymer B.
- the cure time when the radiopaque polymer A and radiopaque polymer B are combined is then measured. In one embodiment, the cure time is less than 15 seconds.
- the sodium diatrizoate molecule has 3 iodine groups attached which aids in radiopacity.
- Sodium diatrizoate in an aqueous solution is subject to degradation. Heat and pH effects the stability.
- 20 grams of Part A and 20 grams of Part B were placed in an oven at 60 C (140 °F) for 8 days. This equals 3 months at ambient temperature (22-25C). There was no material degradation.
- the radiopaque polymer A and radiopaque polymer B of Example 2 are mixed when exiting an applicator.
- the two radiopaque polymers contain different agents that, when mixed together, enable polymerization and cross-linking of the vinyl monomers via the formation of a siloxane bond.
- the resulting topical radiopaque marker substance has a cure time of around 15 seconds and a viscosity of 6500 CPS.
- the shelf life of radiopaque polymer A and radiopaque polymer B of Example 2 is formulated to be 2 years.
- Example 2 Compared to prior art topical radiopaque marker substance (e.g., those mentioned in the patents identified above), the formulation of Example 2 was found to have improved curing times, negligible smearing, improved preparation of the application site (e.g., can use standard preparation like betadine and wipes to clean the interventional site; the prior art substances, e.g., those disclosed in the patents identified above, do not allow for preparation because they dissolve and smear when they interact with preparation agents like betadine or alcohol), and is easily removed from the skin without pain and without leaving a residue. In addition, as compared to Examiner 1 , Example 2 shows a faster cure time, increased viscosity, improved visual appearance of the topical marking, and increased shelf stability.
- a radiopaque polymer A may have a white pigment and a radiopaque polymer B may have a blue pigment wherein the resulting color of the topical radiopaque marker substance has a blue color. It will be appreciated by one of skill in the art that different color pigments are also usable, so long as the color of the resulting topical radiopaque marker substance is visible to a user in normal light.
- the freeform topical radiopaque marking substance in accordance with this disclosure is applied in a two-part mixing apparatus wherein Part A and Part B of the freeform topical radiopaque marking substance as discussed above is mixed during dispensing of the substance from the applicator to a location on a patient.
- Prior two-part mixing applicators are known in the art.
- Examples of such mixers include U.S. Patent No. 10,464,719 entitled Multi-chambered dispenser and process; U.S. Patent No. 7,882,983 entitled Capsule for Two-Component Materials; U.S. Patent No. 10,130,768 entitled Combination Plunger Device for a Dual Chamber Mixing Syringe, each of which is hereby incorporated by reference.
- Such devices are characterized, at least in part, by the mixing together of two components of a substance. Often, a spring and a plunger are used to urge each component out of its respective chamber and into a mixing area at the dispensing end of the device.
- FIG. 8 depicts the mechanism in a filled but static state
- Fig. 9 depicts the mechanism in a dispensing state.
- the mechanism includes dual chambers, 122 and 124 for holding two components to be mixed, e.g., Radiopaque Polymer A and Radiopaque Polymer B, respectively.
- a dual chamber plunger 118 seals the dual chambers 122, 124 and also serves as the means by which the components to be mixed are forced out of the mechanism through the mixer 120.
- a plunger spring 116 is disposed between a rear of the housing 102 and the dual chamber plunger 118.
- the plunger spring 116 is in a compressed or “pre-loaded” state.
- the plunger spring 116 is held in the compressed or “pre-loaded” by the push piece 114 of an actuating rod 112.
- the actuating rod extends from one end where it couples with the dual chamber plunger 118 (via the push piece 114) to its opposite end which sits between a push button 104 and a push button spring 106.
- the actuator rod 112 also has a series of actuator stop notches 110 which interface with at least one corresponding housing stop notch 108 positioned in the housing 102.
- the two components have been loaded into the dual chambers 122, 124, respectively.
- the actuator rod 112 has been situated so as to compress the plunger spring 116 via the push piece 114.
- the actuator rod 112 is secured in this position via the interface and matching shapes of the actuator stop notches 110 and the corresponding housing stop notch 108.
- the push button spring 106 is applying force on the front end of the actuator rod 112 so that it pushes the push button 104 away from the surface of the housing 100.
- each component will be urged through the mixer 120 at the distal end of the mechanism 100.
- the mixer 120 will mix the two components together and the combined, mixed substance will then exit the mechanism.
- the components are a Radiopaque Polymer A and a Radiopaque Polymer B which, when mixed by mixer 120, will exit the device as a topical freeform radiopaque marking substance in accordance with this disclosure.
- the destination of the mixed substance can be a patient’s skin or a surgical drape, for example.
- FIG. 8 A number of possible housings for receiving a dispensing and mixing mechanism such as the mechanism 100 described in one embodiment above are now described.
- the interior structure mixing mechanism of these housings are not restricted to the design set forth in Figs. 8 and 9, but, rather, can be any two-component mixing device known to those of skill in the art that can fit or by modified to fit into the housing device, or variations thereof, as depicted herein
- a housing 200 includes a clip 206 for use in easily securing the device in the pocket of a user.
- a mixer 220 extends from a distal end of the housing 200.
- a push button 204 is located towards a distal end of the housing 200 for mixing and dispensing the two component substances.
- a housing 300 comprises a push button 304 for causing the mixing and dispensing of the two component substances through a mixer 320.
- the housing further includes a movable distal head enabling access to the two- component mixing and application mechanism. This could allow for re-filling of the pen. It could also allow a user to mitigate a clogged dispensing tip.
- the housing 300 includes a slot 330 that receives a plunger location indicator 340.
- the plunger location indicator 340 slides in the slot 330 according to the position of the plunger connected to the dual chambers the housing 300.
- the plunger location indicator 340 is connected to the dual chamber plunger 118.
- the plunger location indicator 340 will slide within the housing slot 330 and thereby provide a visual and tactile indicator to the user of the amount of component substances that have been discharged from the dual chambers 122, 124.
- such an indication will also convey to the user the amount of component substances remaining in the dual chambers 122, 124.
- a housing 400 may have a push button 404 located at the distal end of the housing 400 and also includes a mixer 420. Also located at a distal end of the housing 400 is a window 461 formed by a frame 460 extending around the mixer 420. The window 461 allows a user to observe the mixing of the components as they exit the dual chamber of the mechanism.
- the frame 460 also provides structural support to the mixer 420 for those uses where a greater force may be exerted on the tip of the mixer 420 during dispensing.
- a housing 500 may have push button 504 located at a proximal end of the housing 500 opposite the distal end where the mixer 520 is located.
- the housing 500 may also have a window 562 enabling a user to observe the levels of the component substances contained in the dual chambers.
- the proximal end of the device 563 is contoured. In one embodiment the contour is a beveled or scalloped shape. Such a contoured shape allows a user to spread and arrange the mixed component substance, e.g., a topical freeform radiopaque marker substance, on the patient as needed.
- the housing may also incorporate a self-dispensing tip 564.
- the self-dispensing tip is driven via a different internal mechanism than described in Figs. 8-9.
- the push button 504 is instead a release latch that allows an internal spring to drive a dual chamber plunger.
- the dual chamber plunger urges the two components to flow through the mixer.
- the user can stop the self-dispensing by pressing the release latch once more.
- the spring is then engaged and the force on the dual chamber plunger is halted.
- a housing 600 may include a push button 604 for mixing and dispensing the two-component substance through an exit hole 665.
- the mixer is not shown as it is recessed inside the exit hole 665.
- This embodiment has no internal springs to drive a dual plunger.
- the housing for the dual components is made of a compliant polymer bag. This bag is over-sized relative to the dimensions of the housing 600. Due to this physical interference, pressure is exerted on the compliant polymer bag when the two halves of the housing are assembled during manufacturing.
- the push button 604 is attached to a compliant valve that opens upon pressing the push button 604.
- the housing also may have a fin 666 disposed on the nose of the housing 600. The fin 666 enables a user to spread the mixed two component substance after it has been dispensed through the exit hole 665.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A radio-opaque composition is formulated to enable a clinician, technician, or alternative user to apply custom markings to a surface, such as a patient's skin or a surgical drape on the patient. More specifically, the radio-opaque composition may be used to write on the surface. The markings may be well-defined and contrast with the surface to which they are applied. Such a composition may include the mixing of two components, each component having a silicone polymer base with radiopaque agents.
Description
SPECIFICATION
RADIOPAQUE MARKING COMPOSITIONS AND DELIVERY THEREOF
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application Serial No. 63/123,867 filed December 10, 2020 entitled Radiopaque Markers and Devices and U.S. Provisional Application Serial No. 63,126,431 filed December 16, 2020 entitled Radiopaque Markers and Devices, each of which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
[0002] This disclosure relates to radiopaque marking mediums that are also visible in normal light, and particularly to topical radiopaque marking substances and delivery mechanisms therefor.
BACKGROUND
[0003] Topical radiopaque markings are used to delineate anatomical locations in a variety of clinical settings and scenarios. In image-guided surgery, topical markings are used to provide a precise correlation between the patient and their scanned images. Examples include the following: In diagnostic imaging, topical markings are used to define anatomical locations and to orient the interpreting clinician. In cardiovascular surgery, topical markings are used to define vascular access sites, to size anatomic organs, to define implant location, and to size implants. In select vascular applications like diabetic amputations, topical markings may be used to specifically guide amputation location. In interventional radiology, topical markings are used to guide procedures like CT-guided lung biopsy.
[0004] Other clinical applications include: Bone screws - marking skin entry site; Biliary intervention - triangulating anatomy; Ablation - uses picture of stick area, line up with laser, prep over (chlorohexidine), then puncture through x-marks; Chest tube placement - targeting with CT and making mark with CT and go through with x-ray; G-tube placement - mark colon on scan as a reference point to avoid; Nephrostomy
tube placement - mark relevant structures to avoid; Fistula de-clotting; Stent placement; and, Bone/wire fixation in plastic surgery.
[0005] These applications represent a diverse set of clinical settings and scenarios wherein, for example, radiologists, interventional radiologists, vascular surgeons, interventional cardiologists, and radiologic technicians could use topical markings to guide interventions or diagnostic interpretations.
[0006] In 2006, there were 17 million interventional procedures using radiologic imaging and approximately 360 million diagnostic radiologic imaging scans. Mettler, F. A. et al. Radiologic and nuclear medicine studies in the United States and worldwide: Frequency, radiation dose, and comparison with other radiation sources - 1950-2007. Radiology 253, 520-531 (2009). There are numerous producers of topical markings intended for use in conjunction with radiologic imaging. Several of these producers include: Izi Medical, Beekley Medical, Webb Medical, Viscot, LeMaitre, and Speed-E-Mark.
[0007] Current topical radiopaque markers consist of stickers, placards, rulers, “BBs”, and lines. These markings are used to identify anatomical sites and targets for intervention in procedures that utilize radiologic imaging. However, no single marking device can be used in all applications because no conformal, flexible marking instrument is known to exist. This leads to scenarios in which other medical equipment must be used to meet the need of the user. For example, hemostats are often used to mark the head of the femoral artery during femoral artery access for interventional cardio-vascular procedures.
[0008] In still other procedures, users place freeform markings on a patient’s skin, but these cannot be seen simultaneously under imaging. Burden on the physician could be reduced by a freeform marker that can be used also under imaging.
[0009] The only known freeform radiopaque marking comes in the form of a tattoo However, a tattoo leaves a permanently visible mark on a patient’s skin and is consequently undesirable.
[0010] Prior art freeform topical radiopaque markings are known. U.S. Patent No. 9,861 ,449 entitled Radiopaque Marking Implant (incorporated herein by reference)
discloses a crayon-like marker that applies a topical marking. However, the marking is prone to smearing and is not easily and/or cleanly removed from a patient’s skin. U.S. Patent No. 10,709,800 entitled Radiopaque Writing Instruments and Methods of Use (incorporated herein by reference) discloses a liquid marker used to apply a topical marking. However, the marking is prone to smearing, does not apply evenly, dries too slowly and is not easily removed from the patient’s skin.
[0011] In view of the foregoing, it is evident that a flexible, freeform marking suitable for any application using radiologic imaging is needed and that such marking has one or more of the following attributes: it applies evenly and efficiently, dries rapidly, it does not smear, that a puncture or incision can be made therethrough, it does not create an unsuitable imaging artifact, and is easily removed (i.e., without pain or the need of solvents). Other desirable attributes will be appreciated and understood by those of skill in the art.
SUMMARY
[0012] This disclosure includes compositions and devices for marking a patient's skin or a covering thereon. A marking composition according to this disclosure, which may also be referred to as an “ink,” may provide a mark that is visible to an individual when viewed directly and in images obtained from one or more common imaging modalities (e.g., x-ray, fluoroscopy, CT, etc.). The marking composition may be formulated to enable a clinician to mark a patient's skin clearly and accurately to provide a well-defined and unambiguous marking that contrasts with the surface to which it is applied and that indicates the identity of the patient, the site (e.g., surgical location, etc.) where the patient is to be treated, and/or the procedure, or treatment approach, to be taken, including any patient-specific details of the procedure.
[0013] The marking composition of the present disclosure may be formulated by two components, each of which being composed by at least 50% radiopaque agent in order to provide adequate visibility under radiologic imaging. Lower concentrations of radiopaque agent may be used for more viscous formulations that apply more thickly; however, this increase in viscosity leads to undesirable delivery properties. The radiopaque agent may itself be composed of multiple radiopaque agents.
[0014] In one embodiment the two components are each composed of around 53.6% radiopaque agent. In one embodiment the two components are each composed of around 54% radiopaque agent.
[0015] However, it should be understood by the present disclosure that the composition of the at least two components should be a minimum of 50% radiopaque agent. The applied layer thickness is preferred to be less than 1.5mm. It should be further understood that the components need not each be composed of at least 50% radiopaque agent as long as the composite marking composition, comprised of the two components, of the present disclosure itself is composed of at least 50% radiopaque agent. For example, the two components could each be composed of 25% radiopaque agent and 75% radiopaque agent, respectively, such that, when combined, the composite marking composition is at least 50% radiopaque agent.
[0016] The two components may be comprised of a silicone base.
[0017] The two components are further comprised of a silicone polymer that includes silica, either particulate silica or fumed silica.
[0018] A topical radiopaque marking composition of the present disclosure may include a first radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the first radiopaque polymer component; and a second radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the second radiopaque polymer component; wherein the first radiopaque polymer component and said second radiopaque polymer component are mixable to form one topical radiopaque marking substance.
[0019] A method of applying a topical radiopaque marking substance of the present disclosure may include providing a radiopaque polymer A and a radiopaque polymer B, each of which having a radiopaque agent content of at least 50% and then mixing the radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance; and performing the mixing just prior to applying the topical radiopaque marking substance to a target site.
[0020] A method of making a topical radiopaque marking substance of the present disclosure may include providing a silicone base; formulating a silicone polymer A and a silicone polymer B from the silicone base wherein the composition of silicone polymer A is different than the composition of silicone polymer A; adding at least one radiopaque substance to each of silicone polymer A and silicone polymer B to form a radiopaque polymer A and a radiopaque polymer B, respectively; and, mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
[0021] A method of making a topical radiopaque marking substance of the present disclosure may include providing a silicone base; formulating a silicone polymer from said silicone base; adding at least one radiopaque substance to the silicone polymer to form a radiopaque base; formulating a radiopaque polymer A and a radiopaque polymer B from the radiopaque base, wherein the composition of radiopaque polymer A is different from the composition of radiopaque polymer B; and mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
[0022] A device for delivering a topical radiopaque marking substance in accordance with the present disclosure may include dual chambers disposed in the housing, one chamber containing a silicone based radiopaque polymer A and one chamber containing a silicone based radiopaque polymer B; a mixer disposed at a distal end of the housing; a dual chamber plunger interoperative with the dual chamber; a spring for urging movement of the dual chamber plunger into said dual chamber; and a push button to actuate movement of the dual chamber plunger.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] These and other aspects, features and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which
[0024] Figs. 1 is two photographs, both of the same hand with a topical radiopaque composition in accordance with the present disclosure, one photograph in normal light and one photograph under radiologic imaging;
[0025] Fig. 2 is a photograph of an animal with a topical radiopaque composition in accordance with the present disclosure when viewed in normal light;
[0026] Fig. 3 is a photograph of the animal of Fig. 2 when viewed under fluoroscopic radiologic imaging;
[0027] Fig. 4 is series of photographs of a topical radiopaque composition in accordance with the present disclosure, one under normal light and two under computed tomography (CT) imaging;
[0028] Fig. 5 is a photograph of a topical radiopaque composition in accordance with the present disclosure being removed from the skin of subject;
[0029] Fig. 6 is a flow chart for a formulation of a topical radiopaque composition in accordance with the present disclosure;
[0030] Fig. 7 is a flow chart for a formulation of a topical radiopaque composition in accordance with the present disclosure
[0031] Fig. 8 is a cross-sectional schematic view of a mixer and applicator mechanism for a dual component substance in accordance with the present disclosure;
[0032] Fig. 9 is a cross-sectional schematic view of a mixer and applicator mechanism for a dual component substance in accordance with the present disclosure;
[0033] Fig. 10 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure;
[0034] Figs 11A-11 C are perspective views of a housing usable with a dual component mixer and applicator in accordance with the present disclosure;
[0035] Fig. 12 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure;
[0036] Figs 13A-13B are perspective views of a housing usable with a dual component mixer and applicator in accordance with the present disclosure; and,
[0037] Fig. 14 is a perspective view of a housing usable with a dual component mixer and applicator in accordance with the present disclosure.
DETAILED DESCRIPTION
[0038] Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.
[0039] This disclosure is directed to a topical freeform radiopaque marking composition and a marking mechanism useful in making clear and unambiguous markings on a patient in preparation for medical procedures such as surgeries and other procedures, and particularly in surgeries and procedures that require radiographic imaging (e.g., X-Ray, CT scanning, fluoroscopy, SPECT, MRI, PET-CT, MRA, nuclear medicine scans). The markings may identify the patient, one or more treatment sites on the patient, the procedure(s) to be conducted at each treatment site (e.g., surgical approaches, etc.), one or more anatomic landmarks, the interventional approach or the like. The markings are versatile and helpful both in surgeries and procedures that don’t require the aid of radiographic imaging and those that do.
[0040] In one example, a topical freeform radiopaque marking composition in accordance with this disclosure is shown Figs. 1 -3 in connection with a procedure involving hand surgery (Fig. 1 ) and a procedure involving a vascular operation (Figs. 2-3) where the marking composition is clearly seen both under normal vision and in radiographic imaging.
[0041] In another example, the topical freeform radiopaque marking composition in accordance with this disclosure is useful in CT imaging as shown in Fig. 4. In this example, a grid is drawn on a torso phantom in a simulated CT-guided lung biopsy. The far left photos is the composition in normal light and the remaining two photos show the composition in CT images. The marking composition is visible and shows no imaging artifact.
[0042] The topical freeform radiopaque composition is also easily removable from the skin of a patient as shown in Fig. 5.
[0043] It has been determined that a topical freeform radiopaque marking composition according to this disclosure has superior properties in its viewing properties under radiographic imaging, in its non-smearing properties, in its ease in removal from a patient’s skin; in its ease in delivery and in its versatility.
[0044] One reason for the superior properties may be that the topical freeform radiopaque marking composition has a radiopaque agent that makes up at least 50% of the composition. Another reason may be that it is formulated from a silicone base. Another reason may be that its viscosity is in a range of 5000-7500 CPS, preferably 6500 CPS. Another reason may be that its cure time is in a range of 10 seconds to 3 minutes, and preferably 10 seconds to 60 seconds. Another reason may be that it is comprised of two components that polymerize and cross-link when mixed.
[0045] Similarly, the topical radiopaque marking composition of the present disclosure need not be formulated from only two components. As will be appreciated by one of skill in the art, more than two components could be used without departing from the scope of this disclosure and still arrive at a topical radiopaque marking composition that has at least 50% radiopaque composition, has a viscosity in a range of 5000-7500 CPS and a cure time in a range of 10 seconds to 3 minutes. In this regard, the example formulations contained herein are not limiting to the scope of the invention..
[0046] I. Topical Freeform Radiopaque Marking Composition
[0047] A topical freeform radiopaque marking composition according to this disclosure may comprise two components which, when mixed together, provide a
topical freeform radiopaque marking substance. Each component may include one or more radio-opaque components. Each component may include a silicone base. Each component may also include a pigment. Each component may include one or more of the following: a siloxane, a chain extender and a cross-linker. Each component may have a radiopaque agent of over 50%.
[0048] The formulations set forth below are non-limiting examples for a topical radiopaque marking composition of the present disclosure. One of ordinary skill in the art will appreciate that modifications to these formulations can be made and still arrive at a radiopaque marking composition that has at least 50% radiopaque agent, a viscosity in a range of 5000-7500 CPS and a cure time in a range of 10 seconds to 3 minutes.
[0049] For example, radiopaque agents and combinations thereof can differ from those disclosed in the examples and still result in a radiopaque marking composition in accordance with the present disclosure.
[0050] For example, different combinations of siloxanes and combinations thereof can differ from those disclosed in the examples and still result in a radiopaque marking composition in accordance with the present disclosure.
[0051] For example, different catalysts, chain extenders and cross-linkers and combinations thereof can differ from those disclosed in the examples and still result in a radiopaque marking composition in accordance with the present disclosure.
[0052] Example 1
[0053] One embodiment of a topical freeform radiopaque marking substance of the present disclosure may have the formulation set forth below:
[0054] Compared to prior art topical radiopaque marker substances (e.g., those mentioned in the patents identified above), the formulation of Example 1 was found to have improved curing times, negligible smearing, reduced preparation time of the application site (e.g., can use standard preparation like betadine and wipes), and is easily removed from the skin as shown in Fig. 5.
[0055] With reference to Fig. 6, the process by which the Radiopaque Polymer A and Radiopaque Polymer B of the chart above may be formed is where a Silicone Base is used to form a Silicone Polymer A and a Silicone Polymer B which, in turn, are used to make Radiopaque Polymer A and Radiopaque Polymer B, respectively. Then, during use, Radiopaque Polymer A and Radiopaque Polymer B are mixed together during ejection from an applicator onto, for example, a patient, in the form of a freeform topical radiopaque marking substance in accordance with this disclosure.
[0056] In one embodiment, the freeform topical radiopaque marker substance of Example 1 may be produced in the following manner:
[0057] The silicone base is produced by mixing HMDZ treated precipitated silica with 10,000 vinyl siloxane.
[0058] The silicone base and the vinyl siloxanes (VIN 70 & VIN 200) to be used in producing Silicone Polymer A and Silicone Polymer B (the “Silicone Polymers”) are weighed out in a container.
[0059] The silicone base and the vinyl siloxanes (VIN 70 and VIN 200) are then mixed using a high speed/high shear disperser blade until homogenous.
[0060] While mixing, the radiopaque agents (barium sulfate, sodium diatrizoate, and bismuth III oxide) are slowly added until a thick mixture is achieved.
[0061] The viscosity of the mixture should be where it is pourable but once poured the mixture will not drip or run. In one embodiment the viscosity is in a range of 6,500 to 7,200 cps).
[0062] Once the radiopaque agents are dispersed, the mixture is placed under a rotator-stator homogenizer and thoroughly mixed until the radiopaque agents are thoroughly dispersed. Once the mixture is homogenous, the mixture is split into two equal parts, Part A and Part B.
[0063] White silicone pigment and a 3% platinum catalyst is added to Part A and mixed using a high-speed disperser blade
[0064] Blue pigment, a chain extender (DH6) and a hydride cross linking agent is added to Part B and mixed using a high-speed disperser blade.
[0065] In one embodiment, the mixing process can take between 6-8 hours to achieve a desired viscosity.
[0066] Once thoroughly mixed, the Part A and Part B mixtures are placed in a vacuum chamber until there are no visible bubbles.
[0067] The resulting Part A and Part B mixtures constitute the Radiopaque Polymer A and Radiopaque Polymer B formulations set forth in the chart for Example A.
[0068] During use the radiopaque polymer A and radiopaque polymer B of Example 1 are mixed when exiting an applicator. The two radiopaque polymers contain different agents that, when mixed, enable polymerization and cross-linking of the vinyl monomers via the formation of a siloxane bond. The resulting freeform topical radiopaque marker substance has a cure time of around 3 minutes and a viscosity of 5000 CPS.
[0069] The shelf life of radiopaque polymer A and radiopaque polymer B of Example 1 is formulated to be 1 year.
[0070] In another embodiment, the freeform topical radiopaque marking substance may have a formulation as set forth below.
[0072] With reference to Fig. 7, the process by which the Radiopaque Polymer A and Radiopaque Polymer B of the chart above may be formed is where a Silicone Base is used to form a Silicone Polymer which is then used to form a Radiopaque Base. The Radiopaque Base is then used to form a Radiopaque Polymer A and Radiopaque Polymer B, respectively. Then, during use, Radiopaque Polymer A and Radiopaque Polymer B are mixed together during ejection from an applicator onto, for example, a patient, in the form of a freeform topical radiopaque marking substance in accordance with this disclosure.
[0073] In one embodiment, the freeform topical radiopaque marker substance of Example 2 may be produced in the following manner:
[0074] HMDZ treated fumed silica and 10,000 vinyl siloxane are mixed together to form a silicone base. A quality check may be performed to check viscosity and thixotropic index with expected values being those set forth in Fig. 7
[0075] The silicone base is then mixed together with 200 vinyl siloxane in a plastic container using a Ross mixer to produce a silicone polymer. In one embodiment, the mixing is performed for 30 min.
[0076] In one embodiment, the viscosity of the silicone polymer after mixing at 2 RPM was 912 cps.
[0077] In one embodiment, the viscosity of the silicone polymer after mixing at 20 RPM was 896 cps.
[0078] In one embodiment, the Thixotropic Index of the silicone polymer was 1.018.
[0079] A desired amount of silicone polymer is then move to stainless-steel container and fumed silica is added. Further mixing at high-speed using the ROSS mixer is performed.
[0080] While mixing, sodium diatrizoate is added. In one embodiment the sodium diatrizoate is added over a period of 10-15 minutes.
[0081] Once the sodium diatrizoate is thoroughly dispersed, bismuth III oxide and barium sulfate are added. In one embodiment the mixing is performed for 30-40 minutes.
[0082] The resulting radiopaque base is then placed under a rotor/stator mixer and mixed for 15 min. In one embodiment, the viscosity may be checked for the expected values as set forth in Fig. 7.
[0083] In one embodiment the viscosity of the radiopaque base is 6480 cps.
[0084] The radiopaque base is then placed under vacuum until air is removed.
[0085] To check quality, a sample of the radiopaque base is placed in an 80°F incubator for several days. The viscosity of this sample is again checked for the expected values as set forth in Fig. 7.
[0086] The remainder of the radiopaque base is then divided into 2 equal parts, a Part A and Part B.
[0087] White pigment and 3% platinum catalyst are added to Part A while mixing under a ROSS mixer to form radiopaque polymer A.
[0088] The Part B is placed under a ROSS mixer and while mixing at a medium speed, blue silicone pigment is added. Once the blue pigment is thoroughly mixed in (e.g., 10-15 minutes) DH-6 (hydride chain extender) is added.
[0089] Then the hydride cross linker (Siltech 3H where 3H = 16.1 mmoles/g hydride) is mixed into Part B.
[0090] The resulting compound constitutes radiopaque polymer B.
[0091] In one embodiment, the cure time when the radiopaque polymer A and radiopaque polymer B are combined is then measured. In one embodiment, the cure time is less than 15 seconds.
[0092] The sodium diatrizoate molecule has 3 iodine groups attached which aids in radiopacity. Sodium diatrizoate in an aqueous solution is subject to degradation. Heat and pH effects the stability. In one example 20 grams of Part A and 20 grams of Part B were placed in an oven at 60 C (140 °F) for 8 days. This equals 3 months at ambient temperature (22-25C). There was no material degradation.
[0093] During use the radiopaque polymer A and radiopaque polymer B of Example 2 are mixed when exiting an applicator. The two radiopaque polymers contain different agents that, when mixed together, enable polymerization and cross-linking of the vinyl monomers via the formation of a siloxane bond. The resulting topical radiopaque marker substance has a cure time of around 15 seconds and a viscosity of 6500 CPS.
[0094] The shelf life of radiopaque polymer A and radiopaque polymer B of Example 2 is formulated to be 2 years.
[0095] Compared to prior art topical radiopaque marker substance (e.g., those mentioned in the patents identified above), the formulation of Example 2 was found to have improved curing times, negligible smearing, improved preparation of the application site (e.g., can use standard preparation like betadine and wipes to clean the interventional site; the prior art substances, e.g., those disclosed in the patents identified above, do not allow for preparation because they dissolve and smear when
they interact with preparation agents like betadine or alcohol), and is easily removed from the skin without pain and without leaving a residue. In addition, as compared to Examiner 1 , Example 2 shows a faster cure time, increased viscosity, improved visual appearance of the topical marking, and increased shelf stability.
[0096] In one embodiment, a radiopaque polymer A may have a white pigment and a radiopaque polymer B may have a blue pigment wherein the resulting color of the topical radiopaque marker substance has a blue color. It will be appreciated by one of skill in the art that different color pigments are also usable, so long as the color of the resulting topical radiopaque marker substance is visible to a user in normal light.
[0097] II. Device for Mixing and Applying Freeform Topical Radiopaque Composition.
[0098] In one embodiment, the freeform topical radiopaque marking substance in accordance with this disclosure is applied in a two-part mixing apparatus wherein Part A and Part B of the freeform topical radiopaque marking substance as discussed above is mixed during dispensing of the substance from the applicator to a location on a patient.
[0099] Prior two-part mixing applicators are known in the art. Examples of such mixers include U.S. Patent No. 10,464,719 entitled Multi-chambered dispenser and process; U.S. Patent No. 7,882,983 entitled Capsule for Two-Component Materials; U.S. Patent No. 10,130,768 entitled Combination Plunger Device for a Dual Chamber Mixing Syringe, each of which is hereby incorporated by reference. Such devices are characterized, at least in part, by the mixing together of two components of a substance. Often, a spring and a plunger are used to urge each component out of its respective chamber and into a mixing area at the dispensing end of the device.
[00100] Referring to Figs. 8 and 9, schematic of a mechanism 100 for mixing and applying a two-component topical freeform radiopaque substance in accordance with the present disclosure is shown. Fig. 8 depicts the mechanism in a filled but static state and Fig. 9 depicts the mechanism in a dispensing state.
[00101] The mechanism includes dual chambers, 122 and 124 for holding two components to be mixed, e.g., Radiopaque Polymer A and Radiopaque Polymer B,
respectively. A dual chamber plunger 118 seals the dual chambers 122, 124 and also serves as the means by which the components to be mixed are forced out of the mechanism through the mixer 120.
[00102] A plunger spring 116 is disposed between a rear of the housing 102 and the dual chamber plunger 118. In Fig. 8, the plunger spring 116 is in a compressed or “pre-loaded” state. The plunger spring 116 is held in the compressed or “pre-loaded” by the push piece 114 of an actuating rod 112. The actuating rod extends from one end where it couples with the dual chamber plunger 118 (via the push piece 114) to its opposite end which sits between a push button 104 and a push button spring 106.
[00103] The actuator rod 112 also has a series of actuator stop notches 110 which interface with at least one corresponding housing stop notch 108 positioned in the housing 102.
[00104] As depicted in Fig. 8, the two components have been loaded into the dual chambers 122, 124, respectively. The actuator rod 112 has been situated so as to compress the plunger spring 116 via the push piece 114. The actuator rod 112 is secured in this position via the interface and matching shapes of the actuator stop notches 110 and the corresponding housing stop notch 108.
[00105] Furthermore, the push button spring 106 is applying force on the front end of the actuator rod 112 so that it pushes the push button 104 away from the surface of the housing 100.
[00106] Referring to Fig. 9, when the push button 104 is pressed to overcome the resistance of the push button spring 106, this will cause the actuator stop notches 110 to become disengage or decoupled from the housing stop notches 108. As a result, the plunger spring 116 to exert its force against the push piece 114 of the actuator rod 112 which, in turn, will cause the dual chamber plunger 118 to exert force against each component residing in the dual chambers 122, 124, respectively.
[00107] Each component will be urged through the mixer 120 at the distal end of the mechanism 100. The mixer 120 will mix the two components together and the combined, mixed substance will then exit the mechanism.
[00108] In one embodiment, the components are a Radiopaque Polymer A and a Radiopaque Polymer B which, when mixed by mixer 120, will exit the device as a topical freeform radiopaque marking substance in accordance with this disclosure. The destination of the mixed substance can be a patient’s skin or a surgical drape, for example.
[00109] A number of possible housings for receiving a dispensing and mixing mechanism such as the mechanism 100 described in one embodiment above are now described. As will be appreciated by one of skill in the art, the interior structure mixing mechanism of these housings are not restricted to the design set forth in Figs. 8 and 9, but, rather, can be any two-component mixing device known to those of skill in the art that can fit or by modified to fit into the housing device, or variations thereof, as depicted herein
[00110] Referring to Fig. 10, a housing 200 includes a clip 206 for use in easily securing the device in the pocket of a user. A mixer 220 extends from a distal end of the housing 200. A push button 204 is located towards a distal end of the housing 200 for mixing and dispensing the two component substances.
[00111] Referring to Figs. 11A-11 B, a housing 300 comprises a push button 304 for causing the mixing and dispensing of the two component substances through a mixer 320. The housing further includes a movable distal head enabling access to the two- component mixing and application mechanism. This could allow for re-filling of the pen. It could also allow a user to mitigate a clogged dispensing tip.
[00112] In addition, the housing 300 includes a slot 330 that receives a plunger location indicator 340. The plunger location indicator 340 slides in the slot 330 according to the position of the plunger connected to the dual chambers the housing 300. For example, with reference to the mechanism 100 of Figs. 8 and 9, the plunger location indicator 340 is connected to the dual chamber plunger 118. When the dual plunger spring 116 has caused movement of the dual chamber plunger 118, the plunger location indicator 340 will slide within the housing slot 330 and thereby provide a visual and tactile indicator to the user of the amount of component substances that have been discharged from the dual chambers 122, 124. Of course, such an indication
will also convey to the user the amount of component substances remaining in the dual chambers 122, 124.
[00113] Referring to Fig. 12, a housing 400 may have a push button 404 located at the distal end of the housing 400 and also includes a mixer 420. Also located at a distal end of the housing 400 is a window 461 formed by a frame 460 extending around the mixer 420. The window 461 allows a user to observe the mixing of the components as they exit the dual chamber of the mechanism. The frame 460 also provides structural support to the mixer 420 for those uses where a greater force may be exerted on the tip of the mixer 420 during dispensing.
[00114] Referring to Fig. 13A, a housing 500 may have push button 504 located at a proximal end of the housing 500 opposite the distal end where the mixer 520 is located. The housing 500 may also have a window 562 enabling a user to observe the levels of the component substances contained in the dual chambers. The proximal end of the device 563 is contoured. In one embodiment the contour is a beveled or scalloped shape. Such a contoured shape allows a user to spread and arrange the mixed component substance, e.g., a topical freeform radiopaque marker substance, on the patient as needed.
[00115] Referring to Fig. 13B, the housing may also incorporate a self-dispensing tip 564. The self-dispensing tip is driven via a different internal mechanism than described in Figs. 8-9. In this embodiment, the push button 504 is instead a release latch that allows an internal spring to drive a dual chamber plunger. The dual chamber plunger, in turn, urges the two components to flow through the mixer. The user can stop the self-dispensing by pressing the release latch once more. The spring is then engaged and the force on the dual chamber plunger is halted.
[00116] Referring to Fig. 14, a housing 600 may include a push button 604 for mixing and dispensing the two-component substance through an exit hole 665. The mixer is not shown as it is recessed inside the exit hole 665. This embodiment has no internal springs to drive a dual plunger. Instead, the housing for the dual components is made of a compliant polymer bag. This bag is over-sized relative to the dimensions of the housing 600. Due to this physical interference, pressure is exerted on the compliant polymer bag when the two halves of the housing are assembled during manufacturing.
The push button 604 is attached to a compliant valve that opens upon pressing the push button 604. The housing also may have a fin 666 disposed on the nose of the housing 600. The fin 666 enables a user to spread the mixed two component substance after it has been dispensed through the exit hole 665.
[00117] Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.
Claims
1 . A topical radiopaque marking composition comprising: a first radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the first radiopaque polymer component; a second radiopaque polymer component comprising a silicone polymer and a radiopaque agent, the radiopaque agent making up at least 50% of the second radiopaque polymer component; the first radiopaque polymer component and said second radiopaque polymer component being mixable to form one topical radiopaque marking substance.
2. A topical radiopaque marking composition according to claim 1 , wherein the silicone polymer further comprises a silicone base having either precipitated silica or fumed silica.
3. A topical radiopaque marking composition according to claim 1 , wherein the radiopaque agent comprises a combination of at least two radiopaque substances.
4. A topical radiopaque marking composition according to claim 3, wherein the radiopaque agent comprises three radiopaque substances.
5. A topical radiopaque marking composition according to claim 1 , wherein the radiopaque agent comprises at least one of Barium Sulfate, Sodium Diatrizoate and Bismuth III Oxide.
6. A topical radiopaque marking composition according to claim 1 , wherein the first radiopaque polymer substance further comprises a catalyst.
7. A topical radiopaque marking composition according to claim 1 , wherein the second radiopaque polymer substance further comprises a chain extender and a cross linker.
8. A topical radiopaque marking composition according to claim 1 , wherein the first radiopaque polymer component further comprises a color pigment.
9. A topical radiopaque marking composition according to claim 1 wherein the second radiopaque polymer component further comprises a color pigment.
10. A topical radiopaque marking composition according to claim 1 , wherein the topical radiopaque marking substance has a viscosity of at least 6400 cps.
11. A topical radiopaque marking composition according to claim 1 , wherein the topical radiopaque marking substance has a curing time of less than 15 seconds.
12. A method of applying a topical radiopaque marking substance comprising: providing a radiopaque polymer A and a radiopaque polymer B, each of which having a radiopaque agent content of at least 50%; mixing the radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance; performing the mixing just prior to applying the topical radiopaque marking substance to a target site.
13. A method according to claim 12, further comprising curing the topical radiopaque marking substance in less than 15 seconds.
14. A method according to claim 12, wherein the mixing comprises a polymerization reaction.
15. A method according to claim 12, wherein the radiopaque polymer A and the radiopaque polymer B are each comprised of silicone based radiopaque polymer.
16. A method of making a topical radiopaque marking substance comprising: providing a silicone base; formulating a silicone polymer from said silicone base; adding at least one radiopaque substance to the silicone polymer to form a radiopaque base;
formulating a radiopaque polymer A and a radiopaque polymer B from the radiopaque base, wherein the composition of radiopaque polymer A is different from the composition of radiopaque polymer B; mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
17. A method according to claim 16, wherein the difference in composition comprises radiopaque polymer A having a catalyst and the radiopaque polymer B having a chain extender and a cross linker.
18. A method of making a topical radiopaque marking substance comprising: providing a silicone base; formulating a silicone polymer A and a silicone polymer B from the silicone base wherein the composition of silicone polymer A is different than the composition of silicone polymer A; adding at least one radiopaque substance to each of silicone polymer A and silicone polymer B to form a radiopaque polymer A and a radiopaque polymer B, respectively; mixing radiopaque polymer A and radiopaque polymer B to form the topical radiopaque marking substance.
19. A method according to claim 18, wherein the difference in composition comprises silicone polymer A having a catalyst and silicone polymer B having a chain extender and a cross linker.
20. A device for delivering a topical radiopaque marking substance comprising: a housing; dual chambers disposed in the housing, one chamber containing a silicone based radiopaque polymer A and one chamber containing a silicone based radiopaque polymer B; a mixer disposed at a distal end of the housing; a dual chamber plunger interoperative with the dual chamber;
a spring for urging movement of the dual chamber plunger into said dual chamber; a push button to actuate movement of the dual chamber plunger.
21 . A device according to claim 1 further comprising a clip suitable for securing the device in a pocket of a user.
22. A device according to claim 1 , further comprising a plunger locator indicator disposed on said housing and connected to said dual chamber plunger.
23. A device according to claim 1 , further comprising a window located at the distal end of the housing exposing the mixer for viewing by a user.
24. A device according to claim 1 , further comprising a frame located at a distal end of the housing providing structural support to the mixer.
25. A device according to claim 1 , wherein the housing has a proximal end that is contoured to aid in the movement of the topical radiopaque marking substance at a delivery site.
26. A device according to claim 1 , further comprising a window in the housing exposing the dual chamber.
27. A device according to claim 1 , further comprising a fin disposed on the housing for spreading the topical radiopaque marking substance at a delivery site.
28. A topical radiopaque marking composition comprising: at least 50% radiopaque agent, a viscosity in a range of 5000-7500 CPS; and, a cure time in a range of 10 seconds to 3 minutes.
29. A topical radiopaque marking composition according to claim 28, further comprising polymerized components.
30. A topical radiopaque marking composition according to claim 29, further comprising two polymerized components.
31. A topical radiopaque marking composition according to claim 28, further comprising a silicone base.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063123867P | 2020-12-10 | 2020-12-10 | |
US63/123,867 | 2020-12-10 | ||
US202063126431P | 2020-12-16 | 2020-12-16 | |
US63/126,431 | 2020-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022126124A1 true WO2022126124A1 (en) | 2022-06-16 |
Family
ID=81974035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/072842 WO2022126124A1 (en) | 2020-12-10 | 2021-12-09 | Radiopaque marking compositions and delivery thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022126124A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050064223A1 (en) * | 2003-09-22 | 2005-03-24 | Bavaro Vincent Peter | Polymeric marker with high radiopacity |
WO2015043792A1 (en) * | 2013-09-30 | 2015-04-02 | Danmarks Tekniske Universitet | Silicone chain extender |
US9682230B2 (en) * | 2013-02-26 | 2017-06-20 | Cardiac Pacemakers, Inc. | Implantable medical device including assembly incorporating radiopaque agent and elutable drug into a polymeric lead tip |
WO2018005830A1 (en) * | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
WO2018052951A1 (en) * | 2016-09-14 | 2018-03-22 | Bio-Silicote | Kits, compositions and methods for wound treatment and management |
WO2020243047A1 (en) * | 2019-05-24 | 2020-12-03 | Bambu Vault Llc | Controlled heat delivery compositions |
-
2021
- 2021-12-09 WO PCT/US2021/072842 patent/WO2022126124A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050064223A1 (en) * | 2003-09-22 | 2005-03-24 | Bavaro Vincent Peter | Polymeric marker with high radiopacity |
US9682230B2 (en) * | 2013-02-26 | 2017-06-20 | Cardiac Pacemakers, Inc. | Implantable medical device including assembly incorporating radiopaque agent and elutable drug into a polymeric lead tip |
WO2015043792A1 (en) * | 2013-09-30 | 2015-04-02 | Danmarks Tekniske Universitet | Silicone chain extender |
WO2018005830A1 (en) * | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
WO2018052951A1 (en) * | 2016-09-14 | 2018-03-22 | Bio-Silicote | Kits, compositions and methods for wound treatment and management |
WO2020243047A1 (en) * | 2019-05-24 | 2020-12-03 | Bambu Vault Llc | Controlled heat delivery compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11986359B2 (en) | Multi-mode imaging markers | |
Kühn | Bone cements: up-to-date comparison of physical and chemical properties of commercial materials | |
Linsenmaier et al. | Three-dimensional CT with a modified C-arm image intensifier: feasibility | |
US20080009718A1 (en) | Implements and methods for applying radiopaque markings | |
CA2958861C (en) | Tissue marker for multimodality radiographic imaging | |
Dib et al. | Ultrasonography evaluation of bone lesions of the jaw | |
DE19909816B4 (en) | Navigation system for carrying out and supporting surgical interventions and marking device or fiducial and pointer for such a navigation system | |
WO2015188040A2 (en) | Composition for use in imaging | |
JP7086863B2 (en) | Palpable marker composition | |
DE69105369T2 (en) | Paste composition and process for its preparation. | |
WO2022126124A1 (en) | Radiopaque marking compositions and delivery thereof | |
Shannon et al. | A radiopaque nanoparticle-based ink using PolyJet 3D printing for medical applications | |
US11369696B1 (en) | Radio-opaque writing instruments and methods of use | |
CN210784717U (en) | Marking pen for perspective | |
CN110236696B (en) | Mark pen for perspective | |
CN115177748A (en) | Application of ioversol in preparation of body surface contrast agent and body surface contrast agent | |
CN208926401U (en) | A kind of positioning device of multi-functional fracture CT diagnosis | |
RU2751279C1 (en) | Method for determining the level of the functional spinal unit in spinal operations | |
Eggers | Image-guided surgical navigation | |
US20240071253A1 (en) | System for advanced physician training and patient specific rehearsals | |
Li et al. | Development of an MRI/x-ray/ultrasound compatible marker for pre-operative breast tumour localization | |
TW202411384A (en) | Developing positioning gel, method of producing the same and application thereof | |
Shi | Surgical Navigation in Image-Guided Transoral Robotic Surgery | |
WO2023121630A2 (en) | A guiding drape and application method thereof | |
RU65746U1 (en) | DEVICE FOR X-RAY MARKING OF ZONES OF ANATOMIC OBJECT WHEN RESEARCHED ON A COMPUTER TOMOGRAPH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21904599 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21904599 Country of ref document: EP Kind code of ref document: A1 |